Compare Acadia Healthcare Company Inc (ACHC) vs GSK plc (GSK) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs GSK plc — how do they compare? Acadia Healthcare Company Inc trades at $30.78 (market cap $2.94B), while GSK plc trades at $52.8 (market cap $105.91B). The key difference: GSK plc is far larger — about 36× Acadia Healthcare Company Inc's market cap, and GSK plc pays a 3.38% dividend while Acadia Healthcare Company Inc pays none. Which is the better fit depends on your goals.
| ACHC | GSK | |
|---|---|---|
Market Cap | $2.94B | $105.91B |
Sector | Health | Health |
52-Week High | $31.92 | $61.18 |
52-Week Low | $11.68 | $36.20 |
Enterprise Value | $5.45B | $126.53B |
Dividend Yield | — | 3.38% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
GSK trades at $53.32, down 0.63% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported strong Q1 2026 earnings, beating estimates with $1.24 EPS, and maintains robust profitability with a 17.78% net income margin. Recent FDA approval for Utebzi and the $10.6 billion acquisition of Nuvalent highlight strategic expansion in oncology and anti-infectives.
Outlook remains positive with 7-9% EPS growth guidance for 2026, though risks include integration of large acquisitions and patent cliffs. Analyst consensus is mixed with 31% buy ratings, but solid fundamentals and recent approvals support a constructive view for long-term investors amid sector competition.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →
